Literature DB >> 22343156

Pathologic evaluation of the supraoptic and paraventricular nuclei in dementia.

David Diodati1, Lee Cyn-Ang, Andrew Kertesz, Elizabeth Finger.   

Abstract

BACKGROUND: The neuropeptide oxytocin, produced in the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus, is now understood to function as a neurotransmitter critical for various aspects of social cognition and pro-social behaviour. While patients with Frontotemporal dementia (FTD) display prominent and progressive deficits in such social behaviours, the integrity of these nuclei in FTD is not known.
METHODS: We conducted a quantitative neuropathologic examination of the SON and PVN from patients with FTLD with TDP-43 proteinopathy, Alzheimer's disease, Lewy body disease and controls to determine whether significant pathologic changes or neuronal loss may contribute to the striking behavioural symptoms of FTD.
RESULTS: Contrary to predictions, we found both nuclei to be free of significant pathologic change (TDP-43) in FTLD. In contrast, tau related pathology was found in the PVN in Alzheimer's disease, and alpha-synuclein pathology in the SON in patients with Lewy body dementia.
CONCLUSIONS: These results indicate that the SON and PVN are resistant to FTLD TDP-43 pathology. They also support prior suggestions that the SON is resistant to Alzheimer's disease (AD) related pathology, and extend this to demonstrate SON susceptibility to alpha-synuclein pathology in patients with Lewy body dementia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343156     DOI: 10.1017/s0317167100013251

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  4 in total

1.  Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability.

Authors:  Elizabeth C Finger; Julia MacKinley; Mervin Blair; Lindsay D Oliver; Sarah Jesso; Maria C Tartaglia; Michael Borrie; Jennie Wells; Isabel Dziobek; Stephen Pasternak; Derek G V Mitchell; Katherine Rankin; Andrew Kertesz; Adam Boxer
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

2.  The Role of Oxytocin in Social Circuits and Social Behavior in Dementia.

Authors:  Olivier Piguet; Rebekah M Ahmed; Fiona Kumfor
Journal:  Methods Mol Biol       Date:  2022

3.  Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY).

Authors:  Elizabeth Finger; Scott Berry; Jeffrey Cummings; Kristy Coleman; Robin Hsiung; Howard H Feldman; Adam Boxer
Journal:  Alzheimers Res Ther       Date:  2018-09-27       Impact factor: 6.982

Review 4.  A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art.

Authors:  Chiara Cerami; Giulia Perini; Andrea Panzavolta; Matteo Cotta Ramusino; Alfredo Costa
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.